NCT02092285View on ClinicalTrials.gov

Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)

PHASE4CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

May 9, 2014

Primary Completion Date

May 25, 2016

Study Completion Date

May 25, 2016

Conditions
Ulcerative Colitis
Interventions
DRUG

Golimumab

50mg or 100mg solution for injection; subcutaneous injection

Trial Locations (1)

Unknown

Merck Sharp & Dohme Ltd., Hoddesdon

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02092285 - Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) | Biotech Hunter | Biotech Hunter